Cardiovascular outcomes in fabry disease are linked to severity of chronic kidney disease

Heart

Volumn 101, Issue 4, 2015, Pages 287-293

  Talbot, Andrew S ^a   Lewis, Nigel T ^a   Nicholls, Kathy M ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTIHYPERTENSIVE AGENT;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PERCUTANEOUS CORONARY INTERVENTION; QRS COMPLEX; QT INTERVAL; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; ADOLESCENT; COMPLICATION; DISEASE FREE SURVIVAL; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84921902120     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306278     Document Type: Article

References (30)

1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46.
2. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry' s disease with manifestations confined to the myocardium. New Engl J Med 1991;324:395-9.
3. Mehta A, Clarke JTR, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J Med Genet 2009;46:548-52.
4. Zarate YA, Hopkin RJ. Lysosomal storage disease 3: Fabry' s disease. Lancet 2008;372:1427-35.
5. Thurberg BL, Fallon JT, Mitchell R, et al. Cardiac microvascular pathology in fabry disease-evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009;119:2561-67.
6. Linhart A. The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassman G, eds. Fabry Disease: Perspectives from 5 years of FOS. Chapter 20. Oxford: Oxford PharmaGenesis, 2006.
7. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35.
8. Motwani M, Banypersad S, Woolfson P, et al. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 2012;107:197-202.
9. O'Mahony C, Coats C, Cardona M, et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace 2011;13:1781-88.
10. Eng CM, Guffon N, Wilcox WR, et al. Safety and effi cacy of recombinant human α-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
11. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging Study. Circulation 2003;108:1299-301.
12. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-8.
13. Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013;274:331-41.
14. Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005;46:120-7.
15. Weidemann F, Niemann M Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for better outcome with early treatment. Circulation 2009;119:524-9.
16. Breunig F, Weidemann F, Strotmann J, et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006;69:1216-21.
17. Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009;95:1103-7.
18. Pieroni M, Chimenti C, Ricci R, et al. Early detection of fabry cardiomyopathy by tissue doppler imaging. Circulation 2003;107:1978-84.
19. Sokolow M, Lyon TP. The ventricular complex in the left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-86.
20. Lang RM, Bierig M, Devereux RB, et al . Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiog 2005;18:1440-63.
21. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;59:956-60.
22. Foley RN, Parfrey P, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(Suppl):S112-19.
23. Üçeyler N, Lan H, Schönfeld D, et al. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Periph Nerv Syst 2011;16:304-14.
24. Whalley GA, Marwick TH, Doughty RN, et al. Effect of early initiation of dialysis on cardiac structure and function from the echo study of the IDEAL Trial. Am J Kidney Dis 2013;61:262-70.
25. Dudziak M, Debska-Slizien A, Rutkowski B. Cardiovascular effects of successful renal transplantation: a 30-month study on left ventricular morphology, systolic and diastolic functions. Transplant P 2005;37:1039-43.
26. Mignani R, Panichi V, Giudicissi A, et al . Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 2004;65:1381-85.
27. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiog 2009;10:165-93.
28. Iwabuchi Y, Ogawa T, Inoue T, et al. Elevated E/E' predicts cardiovascular events in hemodialysis patients with preserved systolic function. Internal Med 2012;51:155-60.
29. Wang M, Yip G, Yu C-M, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005;45:272-7.
30. Hillis GS, Møller JE, Pellikka PA, et al. Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 2004;43:360-7.